Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (11-20 of 247) with videos related to

Pageof 25
Sort By:
Recent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.
Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.
Journal of Immunotherapy and Precision Oncology|September 2, 2024
Decentralized Clinical Trials in Early Drug Development-A Framework ProposalDiogo J Silva, Blessie Elizabeth Nelson, Jordi Rodon
The Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small MoleculeJordi Rodon Ahnert, Nathanael Gray, Tony Mok, et al.
Molecular Cancer Therapeutics|September 16, 2008
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trialsJordi Rodon, Victoria DeSantos, Robert Jean Ferry, et al.
Frontiers in Immunology|June 30, 2023
Enhanced antiviral immunity and dampened inflammation in llama lymph nodes upon MERS-CoV sensing: bridging innate and adaptive cellular immune responses in camelid reservoirsJordi Rodon, Nigeer Te, Joaquim Segalés, et al.
Targeted Oncology|December 21, 2016
Immuno-Oncology: The Third Paradigm in Early Drug DevelopmentJuan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, et al.
Pageof 25

Showing results (11-20 of 247) with videos related to

Sort By:
Pageof 25
Recent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.
Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.
Journal of Immunotherapy and Precision Oncology|September 2, 2024
Decentralized Clinical Trials in Early Drug Development-A Framework ProposalDiogo J Silva, Blessie Elizabeth Nelson, Jordi Rodon
The Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small MoleculeJordi Rodon Ahnert, Nathanael Gray, Tony Mok, et al.
Molecular Cancer Therapeutics|September 16, 2008
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trialsJordi Rodon, Victoria DeSantos, Robert Jean Ferry, et al.
Frontiers in Immunology|June 30, 2023
Enhanced antiviral immunity and dampened inflammation in llama lymph nodes upon MERS-CoV sensing: bridging innate and adaptive cellular immune responses in camelid reservoirsJordi Rodon, Nigeer Te, Joaquim Segalés, et al.
Targeted Oncology|December 21, 2016
Immuno-Oncology: The Third Paradigm in Early Drug DevelopmentJuan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, et al.
Pageof 25